Hidradenitis Suppurativa
main-banner
Hidradenitis Suppurativa
CLOU064J12302 Enrolling

Moderate to Severe Hidradenitis Suppurativa Research Study (72 Weeks)


Treatment: Oral Age: 18 Years


Who Can Participate?

Adults (18+) with moderate to severe hidradenitis suppurativa (HS) may participate.

Inclusion Criteria

  • be male or female aged ≥ 18 years
  • have had a diagnosis of HS for 6 months or more
  • have moderate to severe HS, with a total of at least 5 abscess nodules
  • Abcesses and/or inflammatory nodules should affect at least 2 different areas of your body

What Are The Benefits?

  • No cost to participate or receive treatment
  • Regular visits with study doctors who specialise in treating HS (17 visits)
  • Will receive either an investigative oral treatment (study drug) or a placebo
  • Reimbursement for study-related expenses may be provided

How Long Will The Study Last?

  • 72 weeks

Participating Locations

COUNTRY
country-icon
Canada
country-icon
United States

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: June 10, 2025

Official Title

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov ID

NCT06840392

Sponsor

Novartis Pharmaceuticals

Study Description

  • Brief Summary:

    The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

  • Condition or Disease:

    Hidradenitis Suppurativa

  • Intervention/Treatment:

    Drug: Remibrutinib Dose A Drug: Remibrutinib Dose B Drug: Remibrutinib Dose B,Drug: Placebo 1,Drug: Placebo 2
  • Phase:

    PHASE3

  • Ages Eligible for Study:

    18 Years and 100 Years (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Hidradenitis Suppurativa

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content